SCHEMBL4510232

SCHEMBL4510232

Cc1ccccc1CN1CCN(Cc2c(Cl)cccc2Cl)C1=O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 7/20 0.58
CYP1A2 P05177 1/20 0.55
CYP3A4 P08684 1/20 0.55
CYP2D6 P10635 1/20 0.55
CYP2C19 P33261 1/20 0.55
MEN1 O00255 1/20 0.51
KMT2A Q03164 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
DRD2 P14416 1/20 0.51
DRD3 P35462 1/20 0.51
KCNH2 Q12809 1/20 0.51
KDM4E B2RXH2 1/20 0.51
TP53 P04637 1/20 0.50
MAPT P10636 2/20 0.49
PRMT5 O14744 2/20 0.47
WDR77 Q9BQA1 2/20 0.47
TSHR P16473 2/20 0.46
ALDH1A1 P00352 1/20 0.46
GLA P06280 1/20 0.46
GAA P10253 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4509520 0.94 MAPT (0.53) P2RX7CYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL4523295 0.91 CYP1A2 (0.64) P2RX7CYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL4510323 0.88 P2RX7 (0.51) P2RX7CYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL4512688 0.86 KMT2A (0.65) P2RX7CYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL4513935 0.84 CYP2D6 (0.53) P2RX7CYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL4516861 0.83 CYP2D6 (0.58) P2RX7CYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL4511636 0.82 KDM4E (0.66) P2RX7CYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL4514112 0.81 P2RX7 (0.46) P2RX7MEN1KMT2ASMN1; SMN2TP53
SCHEMBL4501138 0.80 CYP2D6 (0.59) CYP1A2CYP3A4CYP2D6CYP2C19MEN1
SCHEMBL4515572 0.80 MAPT (0.67) P2RX7MEN1KMT2ASMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
EP-1864971-A1 PROPHYLACTIC/THERAPEUTIC AGENT FOR DIABETES Takeda Pharmaceutical Company Limited (JP) 2007-12-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes HSD11B1, HSD17B1, HSD11B2 P2RX7 3946/4885CYP1A2 270/4885CYP3A4 671/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.